{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022600","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.154190+00:00","generated_at":"2026-06-22T05:44:21.058012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ORIC reports Q3 2022 cash of $218M; pipeline studies on track for data in 1H 2023","bullets":["Cash and investments of $218.0M as of Sep 30, 2022; expected to fund operations into 2H 2024.","R&D expenses $14.7M (up from $12.9M); G&A $6.0M (up from $5.6M); IPR&D $5.0M milestone for ORIC-114.","Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in 1H 2023.","FDA cleared US IND for ORIC-114; Phase 1b enrolling in South Korea with expansion to US.","Preclinical data on ORIC-533 (CD73 inhibitor) to be presented at ASH Annual Meeting Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022600","json":"https://secwatch.observer/filing/0000950170-22-022600.json","markdown":"https://secwatch.observer/filing/0000950170-22-022600.md","text":"https://secwatch.observer/filing/0000950170-22-022600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/0000950170-22-022600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/oric-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:44:21.058012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c748d7a52d1751bd709f967891f8ab798c1d64d0","claim":"Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/0000950170-22-022600-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}